Proffitt & Goodson Inc. reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 9.4% during the second quarter, according to its most recent filing with the SEC. The fund owned 10,207 shares of the medical equipment provider’s stock after selling 1,054 shares during the period. Zimmer Biomet Holdings comprises 0.6% of Proffitt & Goodson Inc.’s investment portfolio, making the stock its 22nd largest position. Proffitt & Goodson Inc.’s holdings in Zimmer Biomet Holdings were worth $1,311,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Penserra Capital Management LLC boosted its stake in shares of Zimmer Biomet Holdings by 13.0% in the second quarter. Penserra Capital Management LLC now owns 1,456 shares of the medical equipment provider’s stock valued at $186,000 after buying an additional 168 shares during the period. Intrust Bank NA boosted its stake in shares of Zimmer Biomet Holdings by 8.5% in the second quarter. Intrust Bank NA now owns 4,564 shares of the medical equipment provider’s stock valued at $586,000 after buying an additional 359 shares during the period. Geneva Advisors LLC boosted its stake in shares of Zimmer Biomet Holdings by 2.7% in the second quarter. Geneva Advisors LLC now owns 2,107 shares of the medical equipment provider’s stock valued at $271,000 after buying an additional 55 shares during the period. Aviva PLC boosted its stake in shares of Zimmer Biomet Holdings by 1.7% in the second quarter. Aviva PLC now owns 125,260 shares of the medical equipment provider’s stock valued at $16,082,000 after buying an additional 2,110 shares during the period. Finally, Victory Capital Management Inc. boosted its stake in shares of Zimmer Biomet Holdings by 640.1% in the second quarter. Victory Capital Management Inc. now owns 27,072 shares of the medical equipment provider’s stock valued at $3,476,000 after buying an additional 23,414 shares during the period. Hedge funds and other institutional investors own 82.84% of the company’s stock.

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) traded up 0.30% during midday trading on Friday, hitting $113.19. The company had a trading volume of 750,381 shares. The firm’s 50-day moving average is $120.75 and its 200-day moving average is $120.97. The firm has a market capitalization of $22.89 billion, a P/E ratio of 32.24 and a beta of 1.20. Zimmer Biomet Holdings, Inc. has a 12-month low of $95.63 and a 12-month high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing analysts’ consensus estimates of $2.10 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The firm had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.95 billion. During the same period last year, the company posted $2.02 earnings per share. The firm’s quarterly revenue was up 1.1% compared to the same quarter last year. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post $8.24 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.85%. The ex-dividend date of this dividend is Thursday, September 21st. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is presently 27.59%.

ILLEGAL ACTIVITY WARNING: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/08/26/proffitt-goodson-inc-decreases-stake-in-zimmer-biomet-holdings-inc-zbh.html.

Several equities research analysts have commented on the stock. Gabelli assumed coverage on shares of Zimmer Biomet Holdings in a research report on Thursday. They issued a “buy” rating and a $142.00 price target on the stock. Oppenheimer Holdings, Inc. set a $137.00 price target on shares of Zimmer Biomet Holdings and gave the stock a “buy” rating in a research report on Monday, August 14th. Zacks Investment Research cut shares of Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 8th. BidaskClub cut shares of Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Finally, BMO Capital Markets boosted their price target on shares of Zimmer Biomet Holdings from $136.00 to $140.00 and gave the stock an “outperform” rating in a research report on Friday, July 28th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $136.75.

In other news, insider Sang Yi sold 17,731 shares of the stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $124.56, for a total value of $2,208,573.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Tony W. Collins sold 16,986 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The disclosure for this sale can be found here. Corporate insiders own 1.07% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.